0000000000470605

AUTHOR

Volker Moebus

showing 4 related works from this author

German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breas…

2014

1009 Background: Intense dose-dense (idd) epirubicin (E), paclitaxel (T), cyclophosphamide (C) (idd-ETC) resulted in a superior disease-free (DFS) and overall survival (OS) compared to conventional...

GynecologyOncologyCancer Researchmedicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentchemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineOverall survivalIn patientskin and connective tissue diseasesbusinessPrimary breast cancerAdjuvantmedicine.drugEpirubicinJournal of Clinical Oncology
researchProduct

Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metas…

2016

2070Background: In order to improve knowledge about treatment and outcome of breast cancer patients with brain metastases (BM) we initiated the registry Brain Metastases in Breast Cancer Network Ge...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseOutcome (game theory)03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicineskin and connective tissue diseasesbusinessJournal of Clinical Oncology
researchProduct

Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients …

2018

568Background: GAIN-2 compares the effectiveness and safety of a predefined idd regimen (EnPC) vs. a dd regimen with modification of single doses depending on individual hematological and non-hemat...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryNeo adjuvant03 medical and health sciencesRegimen030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinebusinessPathologicalComplete responseEarly breast cancerJournal of Clinical Oncology
researchProduct

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-contr…

2014

1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...

OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct